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Abstract: Vascular smooth muscle cell (VSMC) dedifferentiation is a common feature of vascular
disorders leading to pro-migratory and proliferative phenotypes, a process induced through growth
factor and cytokine signaling cascades. Recently, many studies have demonstrated that small
non-coding RNAs (miRNAs) can induce phenotypic effects on VSMCs in response to vessel injury.
However, most studies have focused on the contribution of individual miRNAs. Our study aimed
to conduct a detailed and unbiased analysis of both guide and passenger miRNA expression in
vascular cells in vitro and disease models in vivo. We analyzed 100 miRNA stem loops by TaqMan
Low Density Array (TLDA) from primary VSMCs in vitro. Intriguingly, we found that a larger
proportion of the passenger strands was significantly dysregulated compared to the guide strands
after exposure to pathological stimuli, such as platelet-derived growth factor (PDGF) and IL-1α.
Similar findings were observed in response to injury in porcine vein grafts and stent models in vivo.
In these studies, we reveal that the miRNA passenger strands are predominantly dysregulated in
response to vascular injury.
Keywords: miRNA expression and regulation; passenger miRNA; biomarker; vascular injury; smooth
muscle cells; porcine vein graft and stent models
1. Introduction
MicroRNAs (miRNAs) are a class of non-coding RNAs known to play a prominent role in gene
regulation at a post-transcriptional level [1–3]. Pri-miRNAs are transcribed by RNA polymerase II and
are processed successively by two RNase III enzymes, Drosha and Dicer, to a ~22 nt miRNA:miRNA *
duplex [4], which, on processing, generates two single-stranded RNA molecules. miRNAs are loaded
onto Argonaute to produce a RNA-induced silencing complex (RISC), which exerts translational
repression via an imperfect binding to the mRNA target, generally localized in the 3′UTR. An equal
amount of the two strands from the miRNA:miRNA * duplex is produced by the transcription but
their accumulation becomes asymmetric [5]. Current miRNA nomenclature provides information on
the direction of the mature miRNA strand using the -3p or -5p suffixes and, normally, the miRNA
guide strand is thought to be the strand that preferentially accumulates in the RISC and the miRNA *
or passenger strand (its partner) is degraded [6]. However, recent studies suggest that these passenger
strands can accumulate in a number of disease pathologies and mediate strand-specific roles based on
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their distinct seed sequences and targets. Indeed, the mature sequences of the two strand forms can
regulate distinct sets of mRNA transcripts or common targets through different hybridization sites on
the mRNA targeted.
miRNAs have been shown to induce phenotypic effects on smooth muscle cells (SMCs) in vascular
disorders. Vascular SMC (VSMCs) within the vessel wall perform both contractile and proliferative
functions in response to diverse cellular stimuli [7]. Under normal physiological conditions, VSMCs
are relatively quiescent, harboring a contractile phenotype responding to changes in vascular flow
to mediate relaxation and contraction. However, vascular injury or insult results in the initiation
of phenotypic switching to a dedifferentiated phenotype. Indeed, the transition of VSMCs from a
differentiated to a dedifferentiated phenotype is a common feature of vascular disorders where VSMCs
harbor pro-proliferative and pro-migratory status. The VSMC phenotype can be modulated by many
environmental cues and triggers, including a number of cytokines and growth factors released in
response to injury. Indeed, platelet-derived growth factor (PDGF) promotes VSMC proliferation and
migration resulting in neointimal formation after artery injury [8,9].
Since there is some recent evidence of the importance of the miRNA passenger strands [10–12],
their individual functions have been studied in settings such as vascular cells with miR-126-5p and
miR-10A*, [13,14] and cancer [15,16]. However, a more detailed or global evaluation of the importance
of the miRNA passenger strands in vascular remodeling is still lacking. As miRNAs emerge as
potential prognostic biomarkers and as attractive targets for disease intervention, we utilized array
technology to evaluate the global expression of miRNA guide and passenger strands from hairpin
precursors in pre-clinical porcine models of vascular injury and human VSMCs.
2. Materials and Methods
2.1. Animals and Tissues
All the procedures for surgery, for the pig vein graft model and the stent model, were performed
in reference [17] and [18], respectively, and were performed in accordance with the UK Home Office
Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 and with the institutional
ethical approval (PPL60/4114 and PPL 60/4429). Male white Landrace pigs (SAC Commercial
Ltd, Edinburgh, UK) were maintained on a 12 h light/dark cycle with free access to food and
water at a designated Biological Procedures Unit. Briefly, the animals (weighing 19–26 kg) were
pre-dosed orally with aspirin and clopidogrel 24 h prior to surgery. The animals were sedated by
intramuscular (IM) injection of Tiletamine/Zolazepam (Zoletil; Virbac, France); general anesthesia
was conducted using intravenous (IV) Propofol (Rapinovet; Schering-Plough, Welwyn Garden City,
UK) and maintained with isoflurane (Abbott Laboratories Ltd, Berkshire, UK). Animals received
100 IU/kg of IV heparin (Leo Laboratories, London, UK) before surgery. After vascular access,
coronary angiography was performed prior to the deployment of either bare metal stents (BMS)
(Gazelle™, Biosensors, Morges, Switzerland) or drug eluting stents (DES) (biolimus A9 eluting stents;
Biomatrix Flex™, Biosensors, Hägglingen, Switzerland). The unstented animals were used as controls.
The pigs received 0.15 mg of buprenorphine IM (Vetergesic: Alstore Ltd, Sheriff Hutton, York, UK)
and 350 mg of ampicillin IM (Amfipen LA, Intervet, UK) immediately following the procedure
and were euthanized after 7 or 28 days by an intravenous overdose of euthatal, and their coronary
vessels carefully removed. For the porcine vein graft surgery, following the induction with Ketaset
(100 mg/mL ketamine hydrochloride), the animals were intubated and anesthetized with halothane
and allowed to spontaneously ventilate. The method for the saphenous vein-carotid interpositional
graft model has been described previously [19]. The saphenous vein was surgically exposed and
harvested from the hind leg by a ‘no-touch’ technique. The vein was cannulated and gently irrigated
with heparinized iso-osmotic sodium chloride (NaCl) solution (0.9 g/L). Each carotid was exposed via
a longitudinal neck incision. The animal was heparinized by the IV administration of 100 IU/kg of
heparin (CP Parmaceuticals Ltd, Wrexham, UK). A 4–5 cm segment of the carotid artery was isolated
Cells 2019, 8, 83 3 of 10
between the vascular clamps and 10 mm was then removed. The residual ends were beveled at 45◦
and a small longitudinal incision was made to lengthen the anastomotic area. The ends of the vein
were similarly beveled and anastomosed as an interposition graft under optical magnification using
continuous 7/0 Surgipro (auto Suture, Dagford, UK) sutures. The saphenous veins from the ungrafted
animals were used as controls. The animals were recovered, returned to their pen and maintained on a
normal chow diet for the duration of the experiment.
Surplus human saphenous vein tissue was obtained with informed consent from patients
undergoing CABG (Coronary Artery Bypass Grafting). All procedures received local ethical approval
(Research Ethical Committee number: 06/S0703/110) and the experimental procedures conformed to
the principles outlined in the Declaration of Helsinki.
2.2. Vessel Storage and RNA Isolation from the Pig Vein Graft Model and Stent Model
All the procedures for RNA extraction from the pig vein graft model and stent model are
described in detail in [17,18], respectively. Briefly, the harvested vessels were placed in RNAlater®-ice
(Invitrogen, Paisley, UK) and stored at −80 ◦C until the day of isolation. RNAs from the veins or
arteries were isolated following disruption of the vessels under liquid nitrogen using a pestle and
mortar, and these vessel fragments were placed in Qiazol (Qiagen, Hilden, Germany) and homogenized
using a tissue homogenizer (Polytron, Switzerland). The RNAs were processed through miRNEasy
Mini Kit (Qiagen) following the manufacturer’s instructions, treated with DNAse 1 (amplification
grade; Sigma, St. Louis, MO, USA) in order to eliminate genomic DNA contamination and quantified
using a NanoDrop ND-1000 Spectrophotometer (Nano-Drop Technologies, Wilmington, DE, USA).
RNA integrity was assessed using the RNA 6000 Nano LabChip kit (Agilent Technologies,
Santa Clara, CA, USA). Only The RNAs with an RNA integrity number value >7 were used for
the TLDA experiments.
2.3. Cell Culture
VSMCs were isolated from human saphenous vein segments within 24 h of surgery using the
explant technique as previously described by Southgate et al. [20]. Briefly, following removal of the
adventitial layer using sterile forceps and scissors, the vein was longitudinally opened. The lumenal
surface of the vein was scraped gently with a rubber policeman to remove the endothelium. Using fine
forceps, thin segments of the medial layer were stripped from the vein. The stripped medial segments
were then cut into approximately 1 mm2 pieces using a tissue chopper and then transferred into a
sterile tube containing wash media (DMEM medium supplemented with 2 mmol/L of L-glutamine
(Invitrogen), 50 µg/mL of penicillin (Life Technologies, Paisley, UK) and 50 µg/L of streptomycin
(Life Technologies)). Following two washes in the wash media, the segments were resuspended
in a small volume of SMC complete medium (SMC growth medium 2 (PromoCell, Heidelberg,
Germany) supplemented with 15% foetal calf serum (FCS) (PAA laboratories, Yeovil, UK), 2 mmol/L
of L-glutamine (Invitrogen), 50 µg/mL of penicillin (Life Technologies) and 50 µg/L of streptomycin
(Life Technologies)) and were then spread onto the base of 25 cm2 tissue culture flasks. Following
overnight culture at 37 ◦C in a humidified atmosphere containing 5% CO2 (v/v), 5 mL of SMC
complete medium was carefully added to each flask. The media were changed every 3–5 days and
after 2–3 weeks, the outgrowth of VSMCs was passaged into 75 cm2 flasks and grown to confluence.
All experiments were performed using VSMCs between passages 3 and 6. The VSMCs were plated
in SMC complete medium, quiesced in medium (DMEM medium supplemented with 2 mmol/L of
L-glutamine (Invitrogen), 50 µg/mL of penicillin (Life Technologies) and 50 µg/L of streptomycin
(Life Technologies)) containing 0.2% FCS for 48 h. The plated cells were either placed in fresh 0.2% FCS
medium (control) or stimulated with 0.2% medium supplemented with PDGF (PDGF-BB, 20 ng/mL)
or with IL-1α (10 ng/mL) or a combination of PDGF and IL-1α for 48 h before RNA isolation.
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2.4. RNA Extraction and Purification
For the extraction of RNAs from VSMCs, the lysis of the plated cells was performed with 700 µL
of QIAzol lysis reagent (Qiagen). The purification of total RNA was achieved using miRNEasy Mini
Kit (Qiagen) according to the manufacturer’s instructions. The RNA integrity and concentration were
determined using the NanoDrop ND-1000 spectrophotometer.
2.5. TaqMan Low Density Array (TLDA) Experiment
miRNA profiling was performed with the Human MicroRNA Array v2.0 Card A and B which
is enabled to quantify 667 human miRNAs catalogued in the miRBase v10. For three independent
patients (Pt 1, Pt 2 and Pt 3), 90 ng of total RNA was reverse transcribed using the Megaplex RT set
pool A and B and then preamplified following the manufacturer’s instructions (Applied Biosystems,
Carlsbad, CA, USA). The cDNA that was produced was loaded on the Human MicroRNA Array
cards and run on the 7900HT Fast Real Time PCR system (Applied Biosystems) using SDS2.3 software.
Data analysis was performed using DataAssist v2.0 Software (Applied Biosystems). The miRNA
expression data were normalized using the RNU48 housekeeper expression because of their low
Ct variance.
The TLDA experiments for the pig vein graft model and the pig stent model are described in
detail in ref [17] and [18], respectively.
2.6. Global Analysis
The literature and databases such as the miRBase Sequence Database (Release 21) permit the
determination of the guide and the passenger strands for a thousand stem loops from the data obtained
by the TLDA experiments. The level of expression (relative expression, %) was classified into three
groups: high (Ct < 23), medium (Ct between 23 and 28) and low (Ct > 28) expressions. The dysregulated
miRNAs are represented by a relative quotient (RQ) higher than two or less than 0.5 in expression level.
2.7. Gene Expression Quantitative RealTime-PCR (qRT-PCR)
The cDNA for gene expression analysis was synthesized from 400 ng of RNA using TaqMan
Reverse Transcription Reagents (Applied Biosystems). The reverse transcription (RT) reactions were
carried out in a volume of 20 µL following the manufacturer’s instructions and run in a thermocycler
under the conditions: 25 ◦C for 10 min, 48 ◦C for 30 min and 95 ◦C for 5 min, then held at 4 ◦C.
The TaqMan real-time PCR reactions were performed in triplicate comprising 5 µL of TaqMan
Universal Master Mix II, no UNG (Applied Biosystems), 0.5 µL of 20× gene-specific primer and a probe
mix (TaqMan gene expression assays, Cat number # 4331182 (CDKN1B, Assay ID: Hs01597588_m1;
UBC, Assay ID: Hs00824723_m1)), 1.2 µL of the reverse transcription product and 3.3 µL of nuclease
free water. RT-PCR was carried out by using a 7900HT Fast Real Time PCR system (Applied Biosystems)
under the conditions: 50 ◦C for 2 min, 95 ◦C for 10 min, and then 40 cycles of 95 ◦C for 15 s, 60 ◦C
for 60 s, then held at 4 ◦C. The gene expression level was normalized to UBC (Ubiquitin C) and the
fold-changes were calculated using the ∆∆CT method.
2.8. miRNA Expression Quantitative RealTime-PCR (qRT-PCR)
All the miRNA specific probes (TaqMan microRNA assays) are commercial and available from Life
Technologies: Cat number # 4427975 (hsa-miR-204, Assay ID: 000508; hsa-miR-218, Assay ID: 000521;
hsa-miR-1275, Assay ID: 002840; hsa-miR-625*, Assay ID: 002432; hsa-miR-222*, Assay ID: 002097).
The RT reactions were performed using the TaqMan miRNA Reverse Transcription Kit
(Applied Biosystems) and miRNA-specific RT stem-loop primers (Applied Biosystems). The RT
reactions were carried out in a volume of 7.5 µL following the manufacturer’s instructions and run in
a thermocycler under the conditions: 16 ◦C for 30 min, 42 ◦C for 45 min and 85 ◦C for 5 min, then held
at 4 ◦C.
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The TaqMan real-time PCR reactions were performed in triplicate comprising 5 µL TaqMan
Universal Master Mix II, no UNG (Applied Biosystems), 0.5 µL of 20 ×miRNA-specific primer and
a probe mix of the TaqMan miRNA Assay Kit (Applied Biosystems), 0.7 µL of the RT product and
3.8 µL of nuclease free water. RT-PCR was carried out by using a 7900HT Fast Real Time PCR system
(Applied Biosystems) under the conditions: 95 ◦C for 10 min, then 40 cycles of 95 ◦C for 15 s, 60 ◦C for
60 s, then held at 4 ◦C. The expression level of miRNA was normalized to RNU48 and the fold-changes
were calculated using the ∆∆CT method. Only the cells from patients harboring a low variation
concerning the baseline expression of miRNAs have been used for the miRNA expression analysis
(Figure S1).
2.9. Statistical Analysis
The statistical analysis was performed according to figure legends. The statement N = 3 means
that three experiments were performed, three independent times, all in triplicate. Data are expressed
as mean ± SEM. Comparisons between the two groups were analyzed using the 2-tailed Student’s
t-test. The one-way ANOVA with Tukey’s post hoc multiple comparison test, via Graph Pad Prism
version 5.0 (GraphPad Software, San Diego, CA, USA), was used for comparisons among three or
more groups. A statistical difference was considered as p < 0.05. Heat maps were generated using the
R program (version 3.2.4) (R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Global Analysis of miRNA in VSMCs in Response to Cytokine and Growth Factor Stimulation and in
Vascular Injury In Vivo
Human VSMCs were treated with PDGF, interleukin 1α (IL-1α) or a combination of both to
mimic a number of the pathologic signals induced by vascular injury. As expected, PDGF induced
a significant increase in VSMC migration (Figure S2A), and the pro-proliferative phenotype was
confirmed by a reduction in the expression of the cyclin-dependent kinase inhibitor 1B (CDKN1B)
(Figure S2B). Following confirmation of the phenotypic alternation in VSMCs, we performed a
detailed and unbiased analysis of both the guide and passenger miRNAs expression in VSMCs
(Table S1). Indeed, using TaqMan Low Density Arrays (TLDA) we were able to quantify a large
number of miRNAs simultaneously in each individual sample. The relative expression in each
condition was compared to the unstimulated quiested VSMCs and expressed in fold change. Globally,
our data highlighted a low variation between the samples. Bioinformatics tools including the miRBase
(Realease 21) (http://www.mirbase.org/) have been used to discriminate “guide” versus “passenger”
strands. We validated five miRNAs from our array by subsequent assays (Figure S3) and found
miRNA markers in our global analysis such as miR-146a, an inflammation-associated miRNA [21],
which showed overexpression following exposure to IL-1α. From our array, the level of expression
was classified into three groups following pre-amplification according to cycle threshold (Ct) values
(low [Ct > 28], medium [Ct between 23 and 28] and high [Ct < 23] expression) for each miRNA.
The global analysis revealed that the miRNA guide strands are more abundantly expressed than the
passenger strands (Figure 1A) in all the conditions tested (Figure S4A). A similar pattern was identified
following the computational analysis of the array data from the porcine models of vein graft failure [17]
and in stent restenosis [18] (Figure S4B and Figure S4C, respectively, Figure 1B and Figure S5). A total
of one hundred hairpins were analyzed from the data generated by TLDA. Consistently across the three
models, we found that the hairpin of miR-10b, miR-193b, miR-199a, miR-214, miR-30a, miR-335 and
miR-99b contained medium or highly expressed passenger strands. Furthermore, a direct comparison
of the relative expression of miRNA strands obtained from their corresponding hairpins confirmed
that the guide strand was more abundantly expressed than its corresponding passenger strand in
more than 60% of cases, a pattern that was consistent across all three data sets (Figure 1C). In human
VSMCs, the guide strand appeared to be the most predominantly expressed variant of the hairpin,
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although there are exceptions where the passenger strands were more abundantly expressed than their
corresponding guide strand such as miR-625 and miR-30a (heat map, Figure 1A). The same type of
exception has been found across the three models for miR-199a, miR-30a, and miR-335.
Figure 1. Low passenger strands expression compared to the guide strands in VSMCs and in vivo.
One hundred hairpins were analyzed by TaqMan Low Density Array (TLDA) in human VSMCs
(average of n = 3), the porcine models of vein graft failure and in stent restenosis (average of n = 6
for both the porcine models, except for the 7 days DES (drug eluting stent) condition, where n = 5).
The level of expression (relative expression, %) was classified into three groups: high (Ct < 23), medium
(Ct between 23 and 28) and low (Ct > 28) expressions. These groups are represented as a % in each pie
chart. (A) Each pie chart represents the global expression of the guide and passenger strands in human
VSMCs. The heat map illustrates the relative abundance of the number of miRNA hairpins that were
consistently expressed across three independent patients and represents the level of expression of the
guide versus passenger strands. (B) Each pie chart represents the global expression of the guide and
passenger strands in the porcine model of in stent restenosis and vein graft failure. (C) Each pie chart
represents the expression of the guide versus passenger strands within each independent hairpin.
3.2. Passenger Strands Are Dysregulated More Frequently than Guide Strands in Vascular Cells and Vascular
Injury In Vivo
Despite their generally lower levels of expression compared to the guide strands, we then
quantified the dysregulation of the passenger strands in vascular cells in vitro and in injury models
in vivo. Interestingly, in all three settings, we found a substantial and predominant dysregulation of the
passenger strands in response to pathological stimuli (Figure 2). The relative number of dysregulated
miRNAs included 39% and 32% of the passenger strands and only 15% and 10% of the guide strands
in human VSMCs treated with PDGF and IL-1α, respectively (Figure 2A). Furthermore, all together,
20% of the dysregulation concerned the two strands in a hairpin. In vivo, 36% and 43% of the passenger
strands were dysregulated compared to 25% and 29% for the guide strands at 7 days following stenting
by BMS (bare-metal stent) and DES (drug eluting stent), respectively (Figure 2B). This dysregulation
was still at 32% and 39% for the passenger strands compared to 19% and 23% for the guide strands at
28 days following stenting by BMS and DES, respectively (Figure S6A). In our vein graft failure model,
Cells 2019, 8, 83 7 of 10
we found 59% of the passenger strands dysregulated compared to 40% the guide strands at 7 days
following engraftment (Figure 2B). This dysregulation reached 68% for the passenger strands and 33%
for the guide strands at 28 days (Figure S6B). Additionally, all together, we found 47% and 31% of the
dysregulation concerned the two strands in a hairpin in the pig vein graft model and in the pig stent
model, respectively.
Figure 2. High passenger strand dysregulation compared to the guide strand dysregulation in
VSMCs and in vivo. The graphs show the percentage of dysregulated miRNAs for each form in
the three independent models. (A) The relative dysregulation of each strand of the miRNA hairpin
was quantified after stimulation by platelet-derived growth factor (PDGF) and IL-1α in human VSMCs
(the statistics have been made between the passenger and guide strands within each condition; unpaired
t-test; ** p < 0.01 for passenger vs guide strands). The heat map illustrates the relative dysregulation
(in relative quotient (RQ)) of a number of miRNA hairpins after stimulation by PDGF and IL-1α across
three independent patient samples (average of n = 3). (B) The dysregulation of the guide and passenger
strands was quantified at 7 days following stenting (BMS (bare-metal stent) or DES (drug eluting stent))
or at 7 days following vein grafting in vivo (n = 6 for both the porcine models, except for the 7 days
in the DES condition where n = 5) (the statistics have been made between the passenger and guide
strands within each condition; unpaired t-test; * p < 0.05 and ** p < 0.01; and vs. the corresponding
control (unstented control animals or saphenous), # p < 0.05 and ### p < 0.001).
4. Discussion
VSMCs are typically quiescent and contractile under normal physiological conditions. However,
following vascular injury, the release of cytokines and growth factors initiates a transcriptional cascade
resulting in the initiation of a process called “phenotypic switching” and this leads the VSMCs to harbor
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a synthetic, pro-proliferative and pro-migratory state. Since miRNAs regulate mRNA expression and
thereby many fundamental biological processes, they are intensely studied as candidates for diagnostic
and prognostic biomarkers in a number of diseases. Indeed, miRNAs have been shown to play
important roles in many cellular processes such as cell differentiation, proliferation and migration.
We decided to conduct a detailed analysis in order to understand the microRNAome through TLDA
in the pre-clinical porcine models of vascular injury and human VSMCs. It is important to note
that we utilized human arrays in the porcine samples to try and identify a miRNA which would
extrapolate to the pathology in the clinical setting, so it is possible that a proportion of miRNAs
may be under-represented due to the sequence variation or chromosomal locations between pig and
human. Our global analysis shows the dysregulation of a number of miRNAs already described in
the literature as phenotypic regulators of VSMCs. For example, we found that miR-222, previously
reported to be involved in vascular pathologies associated with excessive rates of SMC proliferation
and migration [22], was substantially up-regulated in response to pathological stimuli. Indeed, in our
arrays, miR-222 was overexpressed upon PDGF stimulation in VSMCs (Figure 2 and Figure S3) as well
as following DES implantation and vein grafting in the porcine models (Figure S6). Furthermore,
we found that miR-18a was upregulated following vein grafting and stenting in pig models (Figure S6).
This finding is in accordance with the literature, in which miR-18a has been found to be upregulated
after rat carotid balloon injury and to promote VSMC differentiation [23]. Furthermore, miR-145
was downregulated following vein grafting and during the early stage after stenting in our porcine
models (Figure S6). MiR-145 is extensively studied in vascular biology for its ability to control
vascular neointimal lesion formation. Indeed, the restoration of miR-145 in balloon-injured arteries
inhibits neointimal growth in rat [24]. Moreover, our global analysis gave a global landscape of the
miRNA guide strand as well as passenger strand expression. Indeed, recent studies suggest that
these passenger strands can mediate strand-specific roles based on their distinct seed sequences and
targets, highlighting their importance [13,14]. We decided to study the behavior of miRNA depending
on the strand form after exposure to pathological stimuli via our detailed analysis of the miRNA
transcriptome through TLDA. Our results confirmed a higher global expression of the guide strands
compared to passenger strands. Few exceptions with a higher expression of the passenger strands
of the miRNA:miRNA * duplex have been noted, and this suggests the possibility that they can
mediate functional effects on mRNA targets. However, our study is the first to show that a greater
proportion of passenger strand miRNAs was significantly altered after exposure to the pathological
mediators of vascular remodeling, PDGF and/or IL-1α in vitro and post-stenting or grafting in vivo.
Some studies reported a preferred arm switched between samples and tissues [25,26]. In our study,
after vascular injury, the selection of the mature miRNA strand via an “arm switching” mechanism
could be responsible for the greater proportion of the dysregulated passenger strands that was obtained.
It is widely accepted that vascular injury is responsible for the “phenotypic switching” induction in
VSMCs but our study suggests that vascular injury could also be implicated in the aforementioned
miRNA “arm switching” phenomenon.
In conclusion, we demonstrated via a global analysis that the miRNA passenger strands are
frequently dysregulated in acute vascular injury. Our detailed and unbiased analysis emphasized an
interesting landscape of miRNAs in vascular biology where the passenger strands contribute more
broadly than previously thought and may be attractive targets for disease intervention.
Supplementary Materials: The following are available online, Figure S1: Low variation of the baseline miRNAs
expression, Figure S2: Validation of VSMC stimulation, Figure S3: Validation of TLDA arrays expression profiles
by qRT-PCR, Figure S4: Higher expression of the guide strands compared to the passenger strands in VSMCs
and in vivo, Figure S5: Low passenger strands expression compared to the guide strands in stent and vein graft
porcine models, Figure S6: High passenger strands dysregulation compared to the guide strands 28 days following
stenting or grafting in porcine models, Table S1: miRNAs expression analyzed by TLDA in human VSMCs.
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